Telix制药公司通过获得以膀胱癌为重点的FAP定向资产,扩大了癌症治疗选项。 Telix Pharmaceuticals expands cancer treatment options by acquiring FAP-targeting assets, focusing on bladder cancer.

Telix制药公司计划扩大其癌症治疗管道,办法是增加新的资产,以最初侧重于膀胱癌的Fibroblast活化蛋白质(FAP)为目标。 Telix Pharmaceuticals plans to expand its cancer treatment pipeline by adding new assets that target Fibroblast Activation Protein (FAP), initially focusing on bladder cancer. 该公司签订了针对FAP的治疗和诊断性放射药品协定,最初支付700万欧元,有可能根据里程碑增加付款。 The company entered into agreements for FAP-targeting therapeutic and diagnostic radiopharmaceuticals, paying €7 million initially, with potential for additional payments based on milestones. 这些资产旨在通过更准确地针对癌症细胞来改善治疗和诊断结果。 These assets aim to improve treatment and diagnostic outcomes by targeting cancer cells more precisely.